Alto Neuroscience, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Alto Neuroscience, Inc. (ANRO) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $3.55 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-12
- Alto Neuroscience, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $3.55M, a 77.26% increase year-over-year.
- Alto Neuroscience, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $2.82M, a 43.50% increase year-over-year.
- Alto Neuroscience, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $2.19M, a 9.56% increase year-over-year.
- Alto Neuroscience, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $2.00M, a 6.20% increase year-over-year.
- Alto Neuroscience, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $8.11M, a 6.25% increase from fiscal 2024.
- Alto Neuroscience, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $7.63M, a 163.96% increase from fiscal 2023.
- Alto Neuroscience, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $2.89M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.55M 10-Q · filed 2026-08-12 | $6.38M derived: sum of 2 quarters · filed 2026-08-12 | ||
| 2026-03-31 | $2.82M 10-Q · filed 2026-08-12 | |||
| 2025-12-31 | $8.11M 10-K · filed 2026-03-16 | |||
| 2025-09-30 | $2.19M 10-Q · filed 2025-11-12 | $4.19M derived: sum of 2 quarters · filed 2026-08-12 | $6.16M derived: sum of 3 quarters · filed 2026-08-12 | |
| 2025-06-30 | $2.00M 10-Q · filed 2026-08-12 | $3.97M derived: sum of 2 quarters · filed 2026-08-12 | ||
| 2025-03-31 | $1.97M 10-Q · filed 2026-08-12 | |||
| 2024-12-31 | $7.63M 10-K · filed 2026-03-16 | |||
| 2024-09-30 | $2.00M 10-Q · filed 2025-11-12 | $3.89M derived: sum of 2 quarters · filed 2025-11-12 | $6.07M derived: sum of 3 quarters · filed 2025-11-12 | |
| 2024-06-30 | $1.89M 10-Q · filed 2025-11-12 | $4.07M derived: sum of 2 quarters · filed 2025-11-12 | ||
| 2024-03-31 | $2.18M 10-Q · filed 2025-11-12 | |||
| 2023-12-31 | $2.89M 10-K · filed 2025-03-20 | |||
| 2023-09-30 | $541.00K 10-Q · filed 2024-11-12 | $1.80M derived: sum of 2 quarters · filed 2024-11-12 | $2.29M derived: sum of 3 quarters · filed 2024-11-12 | |
| 2023-06-30 | $1.26M 10-Q · filed 2024-11-12 | $1.74M derived: sum of 2 quarters · filed 2024-11-12 | ||
| 2023-03-31 | $484.00K 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |